Journals / MN Oftalmoloji / 2007 / Cilt: 14 - Sayı: 1

The relationship between serum interleukin-2 level and activation of Behçet’s disease

Behçet hastalığında serum interlökin-2 seviyesinin hastalık aktivasyonuyla ilişkisi

Pages
32–36
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The level of IL-2 can be used as a criterion to show the activation of the immune system and the disease, especially in the patients with Behçet’s disease with eye symptoms.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The assessment of serum interleukin-2 level (IL-2) in the Behcet’s disease, and the evaluation of its connection to the disease activation.
📊
Key Findings & Data:Material and Methods: The study group included 19 Behçet’s disease patients with active uveitis.
💡
Conclusion & Impact:Conclusion: The level of IL-2 can be used as a criterion to show the activation of the immune system and the disease, especially in the patients with Behçet’s disease with eye symptoms.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Enzim bağlı immünosorbent tayini · Behçet sendromu · Göz belirtileri

Abstract

Purpose: The assessment of serum interleukin-2 level (IL-2) in the Behcet’s disease, and the evaluation of its connection to the disease activation. Material and Methods: The study group included 19 Behçet’s disease patients with active uveitis. The control groups were composed of 15 Behçet’s disease patients with no eye-involvement (first group), 15 patients with non-active eye-involvement (second group) and 14 normal subjects(third group).The IL-2 level was measured via enzime linked immunosorbent assay (ELİSA) in the serum of the subjects. The average and the standard deviation (SD) of IL-2 levels in all groups were calculated. Results: The mean IL-2 level was 4.52±3.98 U/ml (0.87-14.23) in the active Behçet’s disease group 0.76±0.67 U/ml (0.09-2.17) in the first group, 1.35±0.87 U/ml (0.11-3.02) in the second group, and 0.52 ±0.70 U/ml (0.01-2.11) in the third group. The serum IL-2 level was measured as 1.61±0.68 U/ml (0.87-3.18) in the active Behçet’s disease group with the subjects who have anterior segment (n=9), and as 7.13±3.91 U/ml (0.98-14.23) with the subjects who have posterior segment involvement(n=10). The level of IL-2 was compared among the groups statistically. The difference between the active Behçet’s disease group and the control groups was significant (p=0.001, p=0.007, p=0.001). No significant difference was noticed between control groups 1 and 2 in terms of IL-2 levels. On the other hand the distinction between the anterior and posterior segment involvements, was significant (p=0.002). Conclusion: The level of IL-2 can be used as a criterion to show the activation of the immune system and the disease, especially in the patients with Behçet’s disease with eye symptoms.

Özet

Amaç: Behçet hastalarında serum interlökin-2 (IL-2) düzeyini tespit ederek, bunun hastalık aktivasyonuyla ilişkisini değerlendirmek. Gereç ve Yöntem: Çalışma grubuna aktif üveiti bulunan 19 Behçet hastası, kontrol gruplarına ise Behçet hastalığı (BH) tanısı alan ancak göz tutulumu olmayan 15 hasta (grup1), göz tutulumu olup aktif dönemde olmayan 15 hasta (grup 2) ve 14 normal olgu (grup 3) alındı. Olguların serumlarında, IL-2 seviyeleri enzim bağlı immunosorbent tayin metoduyla (enzyme-linked immunosorbent assay, ELISA) ölçüldü ve tüm grupların IL-2 seviyelerinin ortalamaları ve standart deviasyon (SD) hesaplandı. Bulgular: Ortalama IL-2 seviyesi, aktif Behçet gubunda 4.52±3.98 Ü/ml (0.87-14.23), kontrol gruplarında; grup 1’de 0.76±0.67 Ü/ml (0.09-2.17), grup 2’de 1.35±0.87 Ü/ml (0.11-3.02), grup 3’de ise 0.52±0.70 Ü/ml (0.01-2.11) olarak bulundu. Serum IL-2 düzeyi, aktif Behçet grubunda ön segment tutulumu olan olgularda (n=9) 1.61±0.68 Ü/ml (0.87-3.18), arka segment tutulumu olan olgularda (n=10) 7.13±3.91 Ü/ml (0.98-14.23) olarak bulundu. Serum IL-2 seviyesi, gruplar arasında istatistiksel olarak karşılaştırıldı. Aktif Behçet grubuyla kontrol grupları arasındaki fark anlamlı olarak bulundu (p=0.001, p=0.007, p= 0.001). Kontrol gruplarından grup 1 ve 2 arasında, IL-2 düzeyleri açısından anlamlı bir fark tespit edilmedi ( p=0.052). Ön ve arka segment tutulumunda ise aradaki fark anlamlı idi (p=0.002). Sonuç: Serum IL-2 düzeyinin, özellikle göz bulgularının olduğu Behçet hastalarında, immün sistemin ve hastalığın aktivasyonunu gösteren bir kriter olarak kullanılabileceği sonucuna varıldı.

🔖

Cite This Article

ÖZBOYRAZ, S. İ., ÖZDEMİR, Y., AKSARAY, S., KURAL, G. (2007). The relationship between serum interleukin-2 level and activation of Behçet’s disease. MN Oftalmoloji, Cilt: 14 - Sayı: 1, 32–36. https://ajindex.com/articles/295930

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Rao NA. Uveitis and other intraocular inflammations. In: Yanoff M, Duker JY, editors. Ophthalmology. Philadelphia and Boston: Mosby 2004:1105-15. 2.Şengün A. Behçet hastalığı. Akbatur H, Şengün A editörler. Behçet hastalığı, endoftalmi ve üveitler. Ankara: Barışcan ofset 2002:81-105. 3.Nussenblatt RB. Experimental autoimune uveitis: Mechanisms of disease and clinical therapeutic indications. Invest Ophthalmol Vis Sci 1991
  2. Smith KA. lnterleukin-2. In: Paul WE, editor. Immunology: Recognation and Response. New York: Freeman and Company 1991: 62-70. 5.Sakane T, Suzuki N, Ueda Y, Takada S, Murakawa Y, Hoshino T. Analysis of interleukin-2 activity in patients with Behçet's disease. Ability of T cells to produce and respond to interleukin-2. Arthritis Rheum 1986
  3. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990
  4. Lacomba MS, Martin CM, Chamond RR. Aqueous and serum interferon gamma, Interleukin (IL)-2, IL-4 ve IL-10 in patients with uveitis. Arch Ophthalmol 2000
  5. Ferguson TA, Waldrep JC, Kaplan HJ. The immune response and the eye. The nature of T supressor cell induction in anterior chamber- associated immune deviation (ACAID). J Immunol 1987
  6. Suttorp-Schultern, Rottova A. The possible impact of uveitis in blindness:a literature survey. Br J Ophthalmol 1996
  7. Yazıcı HG, Tüzün Y, Pazarlı H. Influence of age of onset and patient's sex on the prevalance and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 1984
  8. Nussenblatt RB, Whitcup SM, Palestine AG. Concepts of disease pathogenesis. Nussenblatt RB, Whitcup SM, Palestine AG editors. In: Uveitis
  9. Fundamentals and Clinical Practice. St Louis: Mosbyl 996:18-47. 12.Charteris DG, Champ C, Rosenthal AR, Lightman SL. Behçet's disease: activated T lymphocytes in retinal perivasculitis. Br J Ophthalmol 1992
  10. George RK, Chan CC, Whitcup SM, Nussenblatt RB. Ocular immunopathology of Behçet's disease. Surv Ophthalmol 1997
  11. Murray PI, Clay CD, Mappın C, Salmon M. Molecular analysis of resolving immune responses in uveitis. Clin Exp Immunol 1999
  12. Hooks JJ, Chan CC, Detrick B. Identification of the lym-phokines, interferon-gamma and interleukin-2, in inflamatory eye diseases. Invest Ophthalmol 1988
  13. Alpsoy E, Cayırlı C, Er H, Yılmaz E. The levels of plasma interleukin-2 and soluble IL-2R in Behçet disease. J